Sight Sciences, Inc. (NASDAQ:SGHT) EVP Manohar K. Raheja Purchases 10,000 Shares

Sight Sciences, Inc. (NASDAQ:SGHT - Get Free Report) EVP Manohar K. Raheja bought 10,000 shares of the stock in a transaction that occurred on Wednesday, March 12th. The stock was bought at an average price of $2.73 per share, with a total value of $27,300.00. Following the completion of the purchase, the executive vice president now directly owns 145,000 shares in the company, valued at $395,850. This represents a 7.41 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website.

Sight Sciences Trading Up 2.2 %

Shares of SGHT stock traded up $0.06 on Monday, hitting $2.78. 228,179 shares of the stock traded hands, compared to its average volume of 204,784. The firm's 50-day moving average price is $2.80 and its two-hundred day moving average price is $4.23. The company has a debt-to-equity ratio of 0.36, a quick ratio of 9.74 and a current ratio of 10.18. The stock has a market capitalization of $142.71 million, a PE ratio of -2.73 and a beta of 2.52. Sight Sciences, Inc. has a twelve month low of $2.17 and a twelve month high of $8.45.

Sight Sciences (NASDAQ:SGHT - Get Free Report) last posted its earnings results on Wednesday, March 5th. The company reported ($0.23) EPS for the quarter, missing analysts' consensus estimates of ($0.22) by ($0.01). Sight Sciences had a negative net margin of 63.30% and a negative return on equity of 47.28%. The company had revenue of $19.07 million during the quarter, compared to analyst estimates of $18.98 million. During the same period in the previous year, the company earned ($0.22) EPS. As a group, analysts anticipate that Sight Sciences, Inc. will post -0.99 EPS for the current year.

Remove Ads

Institutional Trading of Sight Sciences

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. KCK LTD. acquired a new stake in Sight Sciences during the fourth quarter worth approximately $15,925,000. Barclays PLC raised its holdings in Sight Sciences by 317.4% during the third quarter. Barclays PLC now owns 50,300 shares of the company's stock worth $317,000 after purchasing an additional 38,248 shares in the last quarter. Millrace Asset Group Inc. acquired a new stake in Sight Sciences during the third quarter worth approximately $874,000. Geode Capital Management LLC raised its holdings in Sight Sciences by 1.6% during the third quarter. Geode Capital Management LLC now owns 784,129 shares of the company's stock worth $4,941,000 after purchasing an additional 12,709 shares in the last quarter. Finally, State Street Corp raised its holdings in Sight Sciences by 17.4% during the third quarter. State Street Corp now owns 646,776 shares of the company's stock worth $4,075,000 after purchasing an additional 95,843 shares in the last quarter. Institutional investors and hedge funds own 55.51% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts have commented on SGHT shares. Citigroup decreased their price objective on shares of Sight Sciences from $4.60 to $3.00 and set a "neutral" rating for the company in a research note on Tuesday, March 4th. Piper Sandler cut their price target on shares of Sight Sciences from $5.50 to $3.50 and set a "neutral" rating for the company in a report on Thursday, March 6th. Stifel Nicolaus lowered their target price on shares of Sight Sciences from $5.00 to $4.00 and set a "buy" rating on the stock in a research note on Thursday, March 6th. Needham & Company LLC reaffirmed a "hold" rating on shares of Sight Sciences in a research note on Thursday, March 6th. Finally, UBS Group lowered their target price on shares of Sight Sciences from $5.50 to $5.00 and set a "buy" rating on the stock in a research note on Monday, January 27th. Five analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat.com, Sight Sciences currently has an average rating of "Hold" and a consensus target price of $3.83.

About Sight Sciences

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.